(19)
(11) EP 2 546 649 A3

(12) EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
27.03.2013 Bulletin 2013/13

(43) Date of publication A2:
16.01.2013 Bulletin 2013/03

(21) Application number: 12188223.7

(22) Date of filing: 31.10.2008
(51) International Patent Classification (IPC): 
G01N 33/48(2006.01)
(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

(30) Priority: 02.11.2007 US 984942 P
04.04.2008 US 42459 P

(62) Application number of the earlier application in accordance with Art. 76 EPC:
08845659.5 / 2227689

(71) Applicants:
  • Metabolon Inc.
    Durham, NC 27713 (US)
  • The Cleveland Clinic Foundation
    Cleveland, OH 44195 (US)

(72) Inventors:
  • McCreedy, Bruce J.
    Raleigh, NC 27617 (US)
  • Berger, Alvin
    Raleigh, NC 27614 (US)
  • Hu, Yunfu
    Chapel Hill, NC 27516 (US)
  • Kalhan, Satish C.
    Pepper Pike, OH 44124 (US)

(74) Representative: Main, Malcolm Charles 
Murgitroyd & Company Scotland House 165-169 Scotland Street
Glasgow G5 8PL
Glasgow G5 8PL (GB)

   


(54) Biomarkers for fatty liver disease and methods using the same


(57) The present invention provides various biomarkers of fatty liver disease, including steatosis and steatohepatitis. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of fatty liver disease, methods of determining predisposition to fatty liver disease, methods of monitoring progression/regression of fatty liver disease, methods of assessing efficacy of compositions for treating fatty liver disease, methods of screening compositions for activity in modulating biomarkers of fatty liver disease, methods of treating fatty liver disease, as well as other methods based on biomarkers of fatty liver disease.







Search report


















Search report